Q-omics provides the consensus-scored H2AZ2 profile across patient tissues and cancer cell-line models. H2AZ2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, H2AZ2 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, H2AZ2 RNA expression shows 19,788 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where H2AZ2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2AZ2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2AZ2 survival associations across molecular data types. H2AZ2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2AZ2 RNA expression–survival associations across cancer types. High H2AZ2 expression shows unfavorable associations in MESO, ACC, UVM, LIHC and LGG, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for H2AZ2 RNA expression.
This table summarizes H2AZ2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for H2AZ2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2AZ2 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, COAD, BRCA and STAD. The HNSC box plot shows higher H2AZ2 RNA expression in tumor versus normal tissue (log2 FC = +0.891, t-test p < 0.001).
This table shows molecular features associated with H2AZ2 in patient tissues and cancer cell lines. In patient samples, H2AZ2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, H2AZ2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
